Mochida Pharmaceutical (4534) FY2026 Q3 Earnings Report

Quick View

Executive Summary

Revenue and all four profit indicators increased, resulting in higher revenue and higher profits. Revenue was ¥874.9B (+8.4% YoY), Operating Income was ¥75.3B (+3.9%), Ordinary Income was ¥83.5B (+9.2%), and Net Income attributable to owners of the parent was ¥63.4B (+13.2%). Profit growth accelerated progressively down the income statement, reflecting an increase in non-operating income and a decline in the effective tax rate. EPS was ¥178.91 (¥158.11 in the previous year, +13.2%).

Factors Affecting Business Performance

【Revenue】The Company operates in a single segment, the pharmaceutical-related business, and does not disclose a segment-level breakdown. Revenue increased by +8.4% YoY to ¥874.9B, representing a progress rate of 75.8% against the full-year forecast of ¥1155.0B. As the qualitative information does not specify concrete factors behind the revenue increase, the result can be viewed as company-wide growth.

【Profit and Loss】The gross profit margin was 47.8%, down 3.5pt from 51.4% in the previous year, as Cost of Sales growth (+16.2%) exceeded Revenue growth (+8.4%). Meanwhile, the SG&A expense ratio improved to 39.2% from 42.4% in the previous year, a 3.2pt improvement, partially offsetting the impact of the higher cost ratio. As a result, Operating Income was ¥75.3B (+3.9%), and the Operating Income margin was 8.6%, slightly down from 9.0% in the previous year. Ordinary Income was ¥83.5B (+9.2%), exceeding Operating Income growth, due to contributions from equity in earnings of affiliates of ¥5.9B and an increase in dividend income of ¥4.5B. Extraordinary income and extraordinary losses were both ¥0.02B, and the impact of temporary factors was limited. Net Income was ¥63.4B (+13.2%), exceeding Ordinary Income growth, primarily because the effective tax rate declined from 26.5% in the previous year to 24.0%. Although the Company was affected by higher costs at the operating level, increased non-operating income and a lower tax burden boosted bottom-line growth, resulting in higher revenue and higher profits.

Key Financial Indicators

【Profitability】Against Revenue of ¥874.9B (+8.4% YoY), the gross profit margin was 47.8%, down from 51.4% in the previous year by 3.5pt, indicating the impact of higher costs. Meanwhile, the SG&A expense ratio improved to 39.2% from 42.4% in the previous year by 3.2pt, allowing the Operating Income margin to be maintained at 8.6%, slightly below 9.0% in the previous year. The Net Income margin was 7.2%, improving from 6.9% in the previous year, reflecting the positive impact of non-operating items and the tax burden.【Cash Flow Quality】Cash and deposits were ¥385.0B, down ¥66.5B from ¥451.5B in the same period of the previous year. Accounts receivable increased to ¥402.0B, equivalent to 45.9% of Revenue versus 39.2% in the previous year, indicating that working capital has accumulated at a pace exceeding sales growth. Meanwhile, inventories were ¥205.1B, or 23.4% of Revenue, essentially unchanged from 25.6% in the previous year.【Investment Efficiency】ROE was 4.6% on a nine-month cumulative basis, while the total asset turnover ratio declined slightly to 0.48x from 0.50x in the previous year. Total assets increased by +13.8% YoY to ¥1822.2B, including a substantial increase in investment securities to ¥376.6B (+150.7%), which contributed to the decline in asset efficiency.【Financial Soundness】The Equity Ratio was 75.4%, down from 81.6% in the previous year, but remained at a high level. Interest-bearing debt consisted solely of ¥100.0B in long-term borrowings, newly raised during the period, while the current ratio was 401.2% (current assets of ¥1204.9B/current liabilities of ¥300.3B), indicating strong short-term payment capacity.

Cash Flow Analysis

As the statement of cash flows is not included in the dataset, cash flow trends are analyzed based on changes in the balance sheet. Cash and deposits were ¥385.0B, down ¥66.5B from ¥451.5B in the same period of the previous year. The increase in investment securities (+¥226.4B) appears to have been the main source of cash outflow, while the increase in accounts receivable (+¥85.9B) may also have placed pressure on working capital. On the other hand, the increase in accounts payable (+¥64.9B) and the newly raised ¥100.0B in long-term borrowings provided financial support. Given the recognition of Net Income of ¥63.4B and the ¥35.1B increase in retained earnings to ¥1196.2B, the Company continues to generate profits from its core operations. However, the increased allocation of funds to investment securities and the rise in working capital have reduced cash on hand.

Quality of Earnings

Extraordinary income and extraordinary losses were both ¥0.02B, and the difference between Ordinary Income and Net Income was primarily attributable to changes in income tax expense, indicating a limited impact from temporary factors. Non-operating income of ¥12.2B was mainly driven by dividend income of ¥4.5B (¥3.9B in the previous year) and equity in earnings of affiliates of ¥5.9B. Non-operating expenses of ¥4.0B included a foreign exchange loss of ¥2.5B. Ordinary Income growth (+9.2%) exceeded Operating Income growth (+3.9%) because of the increases in equity in earnings of affiliates and dividend income. Furthermore, Net Income growth (+13.2%) exceeded Ordinary Income growth because the effective tax rate declined from 26.5% in the previous year to 24.0% in the current period. Comprehensive income was ¥95.7B, ¥32.3B higher than Net Income of ¥63.4B, primarily due to a +¥33.6B valuation difference on other securities (OCI). Accordingly, the increase in comprehensive income was largely attributable to the fair-value measurement of held securities and should be distinguished from recurring earnings power in the core business.

Earnings Forecast and Guidance

Progress against the full-year earnings forecast was 75.8% for Revenue (¥874.9B/¥1155.0B), 79.2% for Operating Income (¥75.3B/¥95.0B), 75.9% for Ordinary Income (¥83.5B/¥110.0B), and 75.5% for Net Income (¥63.4B/¥84.0B). These levels are broadly in line with or slightly above the time-based progress rate of approximately 75% after nine months, indicating generally steady progress toward the full-year forecasts. No revisions were announced to the earnings forecast or dividend forecast, and management expects to achieve its initial plans.

Shareholder Returns

Dividends have remained broadly unchanged. An interim dividend of ¥40 per share was paid at the end of Q2, and the full-year dividend forecast also remains ¥40 per share, with no revision to the dividend forecast. Based on the Company’s forecast EPS of ¥236.95, the forecast payout ratio is expected to be 40 yen ÷ ¥236.95 = 16.9%. Given the ample cash and deposits of ¥385.0B and the low level of borrowings, with interest-bearing debt of ¥100.0B, no significant concerns are apparent regarding dividend sustainability. No share repurchase was identified in this document, and dividends remain the primary form of shareholder returns.

Risk Factors

1. Increase in trade receivables and cash collection cycle: Accounts receivable were ¥402.0B, up +27.2% YoY, while the ratio to Revenue increased by +6.8pt to 45.9% from 39.2% in the previous year, indicating that working capital has accumulated at a pace exceeding sales growth (+8.4%).

2. Valuation risk for investment securities: Investment securities increased by +150.7% YoY to ¥376.6B, while the valuation difference on other securities was +¥33.6B (OCI), boosting comprehensive income. Valuation gains may contract or reverse due to market fluctuations.

3. Incurrence of new interest-bearing debt: ¥100.0B in long-term borrowings was newly recorded. The use of funds and future trends in interest expense (¥0.3B) should be monitored.

Industry Benchmark (Reference; Compiled by the Company)

Profitability and Returns

Growth and Capital Efficiency

※Source: Compiled by the Company

Key Takeaways from the Earnings Results

1. The gross profit margin declined by -3.5pt YoY to 47.8%, indicating pressure from higher costs. Meanwhile, the SG&A expense ratio improved by -3.2pt, supporting Operating Income. Changes in the cost structure were reflected in a slight decline in the Operating Income margin to 8.6% from 9.0% in the previous year.

2. Ordinary Income (+9.2%) and Net Income (+13.2%) exceeded Operating Income growth (+3.9%). The increases in equity in earnings of affiliates (¥5.9B) and the decline in the effective tax rate (26.5%→24.0%) indicate that non-operating and tax-related factors boosted bottom-line profit beyond the growth of the core operating business.

3. Comprehensive income of ¥95.7B exceeded Net Income of ¥63.4B by +¥32.3B (+50.9%), primarily due to the valuation difference on held securities (+¥33.6B). In assessing earnings quality, it is important to note that this period’s profit growth included fair-value measurement factors in addition to core business performance.

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly available earnings data. Investment decisions should be made at your own discretion and responsibility, and you should consult a professional as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

Mochida Pharmaceutical delivered solid FY2026 Q3 cumulative earnings growth, although operating-margin dilution and elevated working-capital intensity temper the quality of the headline result. Revenue rose 8.4% year on year to ¥87.49bn. Operating income increased 3.9% to ¥7.53bn, materially lagging sales growth. Ordinary income rose 9.2% to ¥8.35bn, aided by a stronger non-operating income contribution. Net income increased 13.2% to ¥6.34bn, exceeding operating-profit growth. The gross margin declined by approximately 350bp year on year to 47.8%, indicating a materially less favorable product, pricing, or cost mix. The operating margin declined by approximately 37bp to 8.6%, remaining within a reasonable range for a domestic pharmaceutical company but below the level generally associated with high-return innovator pharma. SG&A expenses were effectively flat year on year at ¥34.33bn despite revenue growth, reducing the SG&A-to-sales ratio by about 313bp to 39.2%. This operating-cost discipline partly offset gross-margin pressure. Non-operating income increased to ¥1.22bn from ¥0.50bn, with dividend income of ¥0.46bn and equity-method earnings of ¥0.59bn contributing to ordinary-income resilience. Foreign-exchange losses of ¥0.25bn offset part of this benefit. Net income was not materially affected by extraordinary items, as extraordinary gains and losses were each ¥0.02bn. Comprehensive income of ¥9.57bn exceeded net income by ¥3.23bn, primarily reflecting a positive valuation difference on securities of ¥3.36bn. The balance sheet remains highly liquid, with a 401.3% current ratio and ¥38.50bn of cash and deposits. However, receivables rose 27.2% to ¥40.20bn and payables rose 87.5% to ¥13.91bn, while quality alerts identify a long cash conversion cycle. Full-year guidance was maintained, and Q3 progress is broadly in line with the normal 75% seasonal benchmark. The principal forward issue is whether fourth-quarter sales can be converted into operating profit at the guided full-year margin as gross-margin pressure persists.

Profitability Analysis

Annualized DuPont ROE is 6.2%, decomposed into a 7.2% net profit margin, 0.640x asset turnover, and 1.33x financial leverage. The modest ROE is primarily constrained by low asset turnover and conservative leverage rather than a weak balance sheet. The 7.2% net margin is healthy on an absolute basis but below the 10% level generally associated with superior pharmaceutical profitability. The largest operational change was gross-margin compression: gross profit rose only 1.7% to ¥41.86bn despite 8.4% revenue growth, taking gross margin to 47.8% from approximately 51.4% a year earlier. By contrast, SG&A was nearly unchanged at ¥34.33bn versus ¥34.21bn, providing meaningful operating leverage and lowering the SG&A ratio to 39.2% from approximately 42.4%. Accordingly, operating income grew, but its 3.9% increase remained below revenue growth and operating margin eased to 8.6% from approximately 9.0%. Ordinary income grew faster than operating income because non-operating income increased by ¥0.72bn year on year. Dividend income of ¥0.46bn and equity-method earnings of ¥0.59bn support profit, although these sources are less directly indicative of underlying pharmaceutical operating performance than operating income. The tax burden was normal at 0.760, corresponding to a 24.0% effective tax rate. The interest burden exceeded 1.0x because non-operating income exceeded interest and other non-operating costs; interest expense was only ¥0.03bn and interest coverage was exceptionally strong at 250.87x. The annualized 0.640x asset turnover reflects a sizable asset base, including ¥37.66bn of investment securities, and is a key structural limiter of return on equity. Sustained ROE improvement would therefore require a recovery in gross margin, improved operating-asset productivity, or more productive deployment of the financial investment portfolio.

Growth Assessment

Revenue growth of 8.4% to ¥87.49bn demonstrates favorable top-line momentum. Sales growth exceeded operating-profit growth by 4.5 percentage points, however, showing that the current expansion has not fully translated into incremental operating profitability. Gross profit increased only ¥0.41bn year on year, while the cost of sales increased ¥6.35bn, highlighting cost or product-mix pressure. Flat SG&A limited the impact on operating income and indicates disciplined expense management. The single reporting segment is pharmaceutical-related business, making consolidated growth directly representative of the core business. Management maintained full-year forecasts of ¥115.50bn in revenue, ¥9.50bn in operating income, ¥11.00bn in ordinary income, and ¥8.40bn in net income. Q3 cumulative progress is 75.7% for revenue, 79.2% for operating income, 75.9% for ordinary income, and 75.5% for net income, all within 10 percentage points of the standard 75% Q3 progress rate. The operating-income progress rate is 4.2 percentage points ahead of the seasonal benchmark, supporting the achievability of the unchanged forecast. Achieving guidance implies Q4 revenue of ¥28.01bn and operating income of ¥1.97bn, equivalent to a 7.0% Q4 operating margin. This implied Q4 margin is below the 8.6% Q3 cumulative margin, leaving some cushion provided that revenue momentum and cost control continue. Ordinary income requires ¥2.65bn in Q4, implying continued benefit from non-operating income relative to operating income. For a pharmaceutical company, recurring growth durability will depend on product demand, reimbursement and price conditions, generic competition, and the capacity to protect gross margin while funding development activities.

Financial Health

Financial health is strong from a liquidity and interest-servicing perspective. Current assets of ¥120.49bn cover current liabilities of ¥30.03bn by 4.01x, while the 3.33x quick ratio confirms that liquidity does not depend on inventory liquidation. Working capital is substantial at ¥90.46bn. Cash and deposits of ¥38.50bn alone exceed interest-bearing debt of ¥10.00bn by ¥28.50bn. Interest-bearing debt-to-equity is low at approximately 0.07x, while the reported 0.33x debt-to-equity ratio based on total liabilities remains conservative. Debt represents only 6.8% of total capital, and interest coverage of 250.87x indicates negligible refinancing and debt-service stress. There is no material maturity mismatch evident: current assets exceed current liabilities by ¥90.46bn, whereas disclosed long-term loans are ¥10.00bn. Total equity increased ¥67.37bn year on year to ¥137.43bn, supported by retained earnings and higher valuation differences on securities. Total liabilities increased ¥153.63bn year on year to ¥44.79bn, principally reflecting the addition of ¥100.00bn of long-term loans and a ¥64.88bn increase in trade payables. Investment securities increased ¥226.41bn, or 150.7%, to ¥37.66bn and now represent 20.7% of total assets. This sizable financial-asset allocation supports liquidity and non-operating income but raises sensitivity of comprehensive income and equity to market valuations. Accounts receivable increased ¥85.85bn, or 27.2%, to ¥40.20bn, substantially faster than revenue growth. Intangible assets increased ¥2.76bn, or 30.0%, to ¥11.96bn, but remain limited at 0.7% of total assets and do not create material M&A-related balance-sheet risk. The net defined-benefit liability was ¥35.39bn and should remain a consideration in assessing long-duration obligations, although it is well covered by the equity base.

Notable B/S Changes

Investment securities: +¥226.41bn (+150.7%) to ¥376.63bn - now 20.7% of total assets; strengthens financial-asset resources but increases exposure of equity and comprehensive income to market valuation movements. Accounts receivable: +¥85.85bn (+27.2%) to ¥402.02bn - growth far exceeded the 8.4% sales increase and is consistent with the 126-day DSO alert; collection and cash-conversion trends require close monitoring. Accounts payable: +¥64.88bn (+87.5%) to ¥139.07bn - provides working-capital funding but should be assessed alongside the long 252-day cash conversion cycle and elevated operating obligations. Long-term loans: +¥100.00bn to ¥100.00bn - leverage remains modest relative to equity and cash, but this is a material change in funding structure and contributed to the sharp increase in liabilities. Intangible assets: +¥2.76bn (+30.0%) to ¥11.96bn - the percentage increase is notable, although the balance remains only 0.7% of total assets and is not material to overall asset quality.

Cash Flow Quality

The working-capital profile warrants close attention. Quality alerts identify receivable days of 126 days, well above the 60-day threshold, and the 27.2% year-on-year increase in trade receivables materially outpaced 8.4% revenue growth. This may reflect billing timing, collection terms, customer mix, or delayed conversion of sales into cash; regardless of cause, it increases the risk that accounting earnings are not converted into operating cash on a timely basis. The alerts also identify inventory days of 209 days against a 90-day threshold and a separate inventory-days measure of 123 days against a 60-day threshold. Both flagged measures indicate slow inventory conversion and exposure to demand forecasting, expiry, obsolescence, and inventory-write-down risk that are particularly relevant in pharmaceutical manufacturing. Finished goods were ¥20.51bn, while raw materials were ¥12.39bn and work in process was ¥2.02bn, indicating a substantial inventory commitment across the production cycle. The cash conversion cycle alert of 252 days, versus a 120-day threshold, combines slow collections and inventory turnover into a significant cash-efficiency concern. Trade payables increased 87.5% to ¥13.91bn, and electronically recorded operating obligations rose to ¥1.47bn, partially funding working capital; the unusually rapid rise in supplier obligations should be monitored to determine whether it persists. The root cause of the alerts is therefore the combination of high receivables, high inventory, and increased dependence on supplier financing within the operating cycle. The impact is that operating cash generation may lag reported earnings and may become more volatile if working capital normalizes. Improved receivables collection and inventory turnover would strengthen the quality of the otherwise positive earnings trajectory.

Dividend Sustainability

The interim dividend was ¥40.00 per share. On Q3 cumulative net income of ¥6.34bn, the calculated interim payout ratio is 23.0%, a conservative level. Full-year guidance indicates an ¥80.00 per-share dividend and EPS of ¥236.95, implying a forecast dividend payout ratio of approximately 33.8%. This is well below the 60% sustainability benchmark and leaves a substantial earnings retention buffer. The projected annual dividend cash requirement is approximately ¥2.84bn, based on average shares outstanding of 35.45 million. Retained earnings were ¥119.62bn, providing significant balance-sheet support for distributions. Cash and deposits of ¥38.50bn also provide ample liquidity relative to the expected dividend commitment. No dividend revision was announced. Dividend capacity appears financially robust, but sustainable cash coverage should be judged alongside the elevated receivables, inventories, and cash conversion cycle because these can absorb liquidity even when accounting earnings and retained earnings remain strong.

Risk Assessment

Business risks include Gross-margin risk: gross margin fell approximately 350bp year on year to 47.8%, and operating-income growth of 3.9% lagged revenue growth of 8.4%. Continued product-mix, manufacturing-cost, pricing, or reimbursement pressure could limit earnings conversion., Pharmaceutical inventory risk: elevated inventory-day alerts of 209 days and 123 days indicate slow conversion. In pharmaceuticals, this raises the risk of expiry, obsolescence, demand forecast errors, and future valuation losses., Collection-cycle risk: receivable days of 126 days and a 27.2% increase in receivables to ¥40.20bn could delay cash realization from reported revenue., Industry-specific pricing and competition risk: drug price revisions, reimbursement policy changes, generic competition, and product lifecycle effects can pressure sales growth and gross margin..

Financial risks include Cash-conversion risk: the flagged 252-day cash conversion cycle is more than double the 120-day threshold, increasing the risk that operating cash flow trails accounting profit., Financial-market risk: investment securities rose 150.7% to ¥37.66bn and account for 20.7% of assets. Positive security valuation effects supported comprehensive income, but market declines could reverse accumulated other comprehensive income and weaken equity., Liability-structure change: total liabilities increased ¥153.63bn year on year, including ¥10.00bn of long-term loans and ¥64.88bn of additional trade payables. Liquidity is strong, but the drivers and persistence of this balance-sheet expansion merit monitoring..

Key concerns include Highest priority is the working-capital cycle: high DSO, high DIO, and a long cash conversion cycle could constrain cash generation despite rising net income., Second priority is gross-margin recovery. SG&A discipline has offset margin pressure so far, but flat expenses are not an indefinitely scalable substitute for gross-profit improvement., Third priority is the quality and volatility of non-operating earnings. Ordinary-income growth is partly supported by dividend income, equity-method earnings, and financial assets rather than solely by core operations., The maintained forecast is broadly supported by Q3 progress, but the implied Q4 operating margin of approximately 7.0% should be monitored against ongoing gross-margin trends..

Investment Implications

Key takeaways include Revenue, operating income, ordinary income, and net income all grew year on year, with Q3 cumulative progress broadly consistent with full-year guidance., Operating profitability remains acceptable at an 8.6% margin, but margin direction is unfavorable because gross margin compressed materially., The company has a very strong liquidity position, low interest-bearing leverage, and exceptionally high interest coverage., Working-capital efficiency is the principal financial-quality issue, with alert-level receivable days, inventory days, and cash conversion cycle., Investment securities are a meaningful component of the asset base and a source of both non-operating income and comprehensive-income volatility., The dividend appears conservatively covered by forecast earnings and supported by substantial retained earnings and cash..

Metrics to watch include Gross margin and operating margin versus the FY2026 full-year revenue and operating-income plan, Trade receivables, receivable days, and collection trends, Finished-goods inventory, total inventory days, and inventory valuation charges, Cash conversion cycle and the relationship between supplier payables growth and operating working capital, Contribution of dividend income and equity-method earnings to ordinary income, Market-value movements in the ¥37.66bn investment-securities portfolio, Q4 delivery versus implied revenue of ¥28.01bn and operating income of ¥1.97bn.

Regarding relative positioning, Mochida Pharmaceutical combines a conservative capital structure and substantial liquidity with mid-single-digit annualized ROE and an operating margin that is good rather than sector-leading. Relative financial resilience is strong, while relative operating quality depends on restoring gross-margin momentum and improving working-capital efficiency.